07.30.15
Sanofi
2Q Revenues: €9.4 billion (+16%)
2Q Earnings: €1.8 billion (+20%)
YTD Revenues: €18.2 billion (+14%)
YTD Earnings: €3.6 billion (+16%)
Comments: Diabetes sales neared €2.0 billion in the quarter, up 11% driven by Lantus sales of €1.7 billion, up 10%. Genzyme sales were €907, up 41%. Plavix sales were €545 million, up 28%. Lovenox sales were €433 milion, up 3% Renagel/Renvela sales were up 69% to €231 million. Aprovel sales were €224 million, up 16%. Oncology sales were up 16% to €390 million driven by Aubagio (up 110% to €204 million) and Lemtrada (up 833% to $56 million), as well as Cerezyme, Myozyme, and Fabrazine, up 14%, 24%, and 19%, respectively.
2Q Revenues: €9.4 billion (+16%)
2Q Earnings: €1.8 billion (+20%)
YTD Revenues: €18.2 billion (+14%)
YTD Earnings: €3.6 billion (+16%)
Comments: Diabetes sales neared €2.0 billion in the quarter, up 11% driven by Lantus sales of €1.7 billion, up 10%. Genzyme sales were €907, up 41%. Plavix sales were €545 million, up 28%. Lovenox sales were €433 milion, up 3% Renagel/Renvela sales were up 69% to €231 million. Aprovel sales were €224 million, up 16%. Oncology sales were up 16% to €390 million driven by Aubagio (up 110% to €204 million) and Lemtrada (up 833% to $56 million), as well as Cerezyme, Myozyme, and Fabrazine, up 14%, 24%, and 19%, respectively.